On January 2, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, reported that the Company’s management will present an overview and update for the Company, and host investor meetings at the 36th Annual J.P. Morgan Healthcare Conference (Press release, Supernus, JAN 2, 2018, View Source [SID1234522822]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, January 10, 2018
Time: 12:00 p.m. PT / 3:00 p.m. ET
Place: Westin St. Francis Hotel, San Francisco, CA

Investors interested in arranging a meeting with the Company’s management during these conferences should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company’s website at www.supernus.com. An archived replay of this webcast will be available for 60 days subsequent to the Company’s presentation.

On January 2, 2018 H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of next generation cancer medicines using data science and precision chemistry product engine, reported that Markus Warmuth, M.D., President and CEO of H3 Biomedicine, will present an overview of the company and its 2018 goals at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 9:00 a.m. (PST) at the Westin St. Francis Hotel in San Francisco (Press release, H3 Biomedicine, JAN 2, 2018, View Source [SID1234522809]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Dr. Warmuth is expected to provide details about the company’s data science and precision chemistry product engine and its clinical pipeline of three differentiated, internally-generated cancer therapies, including:

H3B-8800, an oral, potent and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1) that is being developed by H3 Biomedicine as an anticancer therapeutic agent.
H3B-6527, a selective, orally bioavailable, and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4) that is being investigated for the treatment of advanced hepatocellular carcinoma (HCC).
H3B-6545, an orally bioavailable, potent and selective small molecule modulator of wild-type and mutant Estrogen Receptor (ERα).
For more information about H3 Biomedicine’s pipeline, click here.

On January 2, 2018 Eli Lilly and Company (NYSE: LLY) reported that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 (Press release, Eli Lilly, JAN 2, 2018, View Source [SID1234522808]). David A. Ricks, Lilly’s chairman and chief executive officer, will speak from 7:00 p.m. to 7:25 p.m. Eastern time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On January 2, 2018 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that Marc N. Casper, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 3:00 p.m. (PST) at the Westin St. Francis, San Francisco, Calif (Press release, Thermo Fisher Scientific, JAN 2, 2018, View Source [SID1234522807]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the live webcast of the presentation in the Investors section of our website, www.thermofisher.com.

On January 2, 2018 Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, reported that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at the 10th Annual Biotech Showcase, being held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco (Press release, Peregrine Pharmaceuticals, JAN 2, 2018, View Source [SID1234522804]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of this presentation are as follows:

Biotech Showcase 2018
Time/Date: 3:30 p.m. PT on Monday, January 8, 2018
Location: Hilton San Francisco Union Square
Room: Yosemite – B (Ballroom Level)